2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) is a nucleoside analog that selectively inhibits human immunodeficiency and hepatitis B viruses in vitro. In this study, the preclinical pharmacokinetics of racemic FTC in rhesus monkeys following intravenous and oral administration were characterized. The terminal half-life of FTC was independent of the route of administration and averaged 1.34 ± 0.18 h (mean ± standard deviation). Total clearance of FTC was moderate to high, averaging 1.49 ± 0.24 liters/h/kg. Qualitative assessment of urine samples suggests that renal excretion of unchanged FTC was the major route of elimination of the nucleoside. The compound was also eliminated by metabolism and the deaminated biotransformation product 2,3'-dideoxy-5-fluoro-3'-thiauridine (FT]U) was detected in serum and urine. This metabolite has no antiviral activity in human lymphocytes and liver cells. FTC and the metabolite FTU were conjugated, to a minor extent yielding the corresponding glucuronides. No 5-fluorouracil was detected in serum or urine. This is consistent with chromatographic studies using a chiral column that indicated that when racemic FTC is treated with cellular cytidine-deoxycytidine deaminase, the D-(+)-enantiomer of FTC is slowly deaminated to D-(+)-FTU, whereas the L-(-)-enantiomer is essentially resistant to this enzyme. The steady-state volume of distribution of FTC in serum averaged 2.23 ± 0.42 liters/kg, and the nucleoside analog was distributed into the cerebrospinal fluid, which suggests that this drug penetrated the blood-brain barrier. Absorption of FTC after oral administration was rapid, with bioavailabiity averaging 73 ± 6%. Taken together, the results indicate that the unusual L-(-)-enantiomer of FTC should be evaluated further in rhesus monkeys prior to determination of whether this compound is useful for treatment of human immunodeficiency and hepatitis B virus infections.
2,3'-dideoxy-5-fluoro-3'-thiauridine (FT]U) was detected in serum and urine. This metabolite has no antiviral activity in human lymphocytes and liver cells. FTC and the metabolite FTU were conjugated, to a minor extent yielding the corresponding glucuronides. No 5-fluorouracil was detected in serum or urine. This is consistent with chromatographic studies using a chiral column that indicated that when racemic FTC is treated with cellular cytidine-deoxycytidine deaminase, the D-(+)-enantiomer of FTC is slowly deaminated to D-(+)-FTU, whereas the L-(-)-enantiomer is essentially resistant to this enzyme. The steady-state volume of distribution of FTC in serum averaged 2.23 ± 0.42 liters/kg, and the nucleoside analog was distributed into the cerebrospinal fluid, which suggests that this drug penetrated the blood-brain barrier. Absorption of FTC after oral administration was rapid, with bioavailabiity averaging 73 ± 6%. Taken together, the results indicate that the unusual L-(-)-enantiomer of FTC should be evaluated further in rhesus monkeys prior to determination of whether this compound is useful for treatment of human immunodeficiency and hepatitis B virus infections.
Discovery of new antiviral agents with superior virological and pharmacological profiles than currently available drugs remains an important goal for treatment of viral infections caused by human immunodeficiency virus type 1 (HIV-1), HIV-2, and hepatitis B virus (HBV) (29) . 3'-Azido-3'-deoxythymidine, 2',3'-dideoxyinosine, and 2',3'-dideoxycytidine (DDC) are nucleoside analogs that are licensed for treatment of AIDS. These compounds have been studied extensively and found to provide significant benefit to AIDS patients despite their side effects, such as anemia and neutropenia for 3'-azido-3'-deoxythymidine, peripheral neuropathy and pancreatitis for 2',3'-dideoxyinosine, and peripheral neuropathy for DDC (29) . Fortunately, these toxicities can be controlled by reducing the dosage and by using these compounds in combination (22) . Racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) is a new nucleoside analog with unusually potent activity against HIV-1, HIV-2, and HBV in culture, with median effective concentrations in the submicromolar range (10, 11, 24, 27, 28) . The compound is markedly less toxic in certain cells than other, related cytidine analogs. For example, unlike DDC and racemic 2',3'-dideoxy-3'-thiacytidine (BCH-189), FTC does not interfere with mitochondrial DNA synthesis, even at a concentration greater than 200 ,uM (10) . Inhibition of this function by nucleoside analogs has been associated with peripheral neuropathy in humans (4) .
The purpose of this study was to characterize the preclinical pharmacokinetics of FTC in rhesus monkeys prior to studies of this compound with humans. The disposition of FTC was assessed after intravenous (i.v.) and oral (p.o.) administration. The metabolic fate of the nucleoside was also examined.
MATERIALS AND METHODS Chemicals. FTC and 2,3'-dideoxy-5-fluoro-3'-thiauridine (FTU) were synthesized in our laboratories as described by Choi et al. (5) . The detailed synthesis and characterization of these new compounds are described elsewhere (13) . 3'-Deoxy-2',3'-didehydrothymidine was synthesized as described previously (8) . The was linear in the range of 0.1 to 100 p,g/ml, and the lower limit of quantitation was 0.1 p,g/ml (10 ng). The assay for FTU was linear in the range of 0.05 to 100 p,g/ml, and the lower limit of quantitation was 0.05 pg/ml (5 ng). Extraction recoveries of FTC, FTU, and 3'-deoxy-2',3'-didehydrothymidine were 87, 93, and 96%, respectively. The intra-and interday coefficients of variation for the assay were less than 10% for both drugs at all drug concentrations.
To ascertain whether 5-FU was a metabolite of FTC, serum and urine samples were analyzed for 5-FU by a previously described HPLC method (31 Enzyme assays. The concentrations of FTC and FTU glucuronides in urine were determined after the glucuronate was hydrolyzed with 3-glucuronidase (16) . To 100 p.l of urine were added 15 p,l of 0.12 N acetic acid, 100 p1l of 3-glucuronidase (500 U/ml in water), and 35 pl of phosphate buffer, pH 5.8. The solution was mixed and incubated at 37°C in a shaker water bath for 12 h. ,B-Glucuronidase-treated urine was assayed for FTC and FIU as described for urine samples. Glucuronide concentration was calculated as the difference between nucleoside concentrations measured before and after hydrolysis with P-glucuronidase.
The ability of FTC to be deaminated to FTU by cytidinedeoxycytidine deaminase was determined by using extracts obtained from Hep-2 (human epidermoid carcinoma) cells, which were found to have large amounts of this enzyme (21) . The extraction and assay procedure has been described previously (21) .
Pharmacoklnetics. Pharmacokinetic parameters for FTC and its metabolite FTU were calculated by using noncompartmental analysis. Areas under the serum concentrationtime curves (AUCs) and first nonnormalized moments (AUMC) were determined by Lagrange polynomial interpolation and integration from time zero to the last measured sample time (20, 33) , with extrapolation to time infinity by using the least-square terminal slope XA generated by weighted NONLIN least-squares regression (17 by comparison of chromatographic, UV, and mass spectral data on the metabolite with data on an authentic FTU reference sample. Chromatographic retention times for the metabolite and the FTU reference moved coincidentally when various ratios of acetonitrile-sodium acetate buffer were used as the mobile phases. Furthermore, the UV and mass spectra of the metabolite were identical to those of reference FTU. In agreement with the molecular weight of FTU, the fast atom bombardment mass spectrum showed a strong molecular ion at m/e 247. In the electron impact spectrum, there was no molecular ion. However, a major fragment ion at m/e 119 was apparent, which corresponds to 5-FU. The base peak is at m/e 101, which may correspond to the 2-methyl-1,3-oxathiolane ring. We also determined that racemic FTC was a substrate for cytidine-deoxycytidine deaminase obtained from human Hep-2 cells (data not TIME, h shown). Only the D-(+)-enantiomer of FTC is a substrate for this mammalian enzyme. Thus, the results strongly suggest that FTC was metabolized by a deamination pathway in monkeys to yield D-(+)-FTU. Confirmation that the FTU detected in urine was the (+)-enantiomer was obtained by using an HPLC chiral column separation method (data not shown).
Concentrations of FTU in serum following i.v. and p.o. administration of FTC to three rhesus monkeys are also illustrated in Fig. 1 and 2 Tables 1 and 2 , respectively. The ratio of FTC, in urine'were twofold greater than those of the FTC concentrations in CSF-serum after i.v. administration metabolite. FTC glucuronide and FTU glucuronide were averaged 0.10 ± 0.54, while that determined after p.o. drug detected in urine. Concentrations of the glucuronides in administration was 0.068 ± 0.043. These values were statisurine were low, however, accounting for only 5 to 20% of the tically significantly different (P < 0.05). The ratios of FTU total FTC and FTU excreted in urine. The ratio of conjuconcentrations in CSF-serum after i.v. and p.o. administragated FTU to unconjugated FTU in urine was approximately tions averaged 0.036 ± 0.014 and 0.039 ± 0.015, respec-1.5-fold greater after p.o. administration of FTC than after tively. There were no significant differences in this ratio for i.v. administration of the nucleoside. The ratio of conjugated FTU, and the average ratio of concentrations in CSF-serum FTC to unconjugated FTC was independent of the route of for both routes of administration was 0.038 ± 0.013. administration. Renal excretion of unchanged FTC acNone of the animals showed any clinical signs that could counted for the greatest portion of the administered dose be related to drug administration during the 1-week obserfound in urine, while the metabolite FTU was excreted vation period. Similarly, none of the animals showed loss of primarily as unconjugated FTU. It should be noted that urine body weight. Other than a slight decrease in erythrocyte volumes were not measured. Thus, while concentrations of counts, hematocrit, and hemoglobin and a slight increase in the parent nucleoside and metabolite in urine were comthe reticulocyte count, there were no significant changes in pared, renal clearance values could not be calculated. Furthe hemogram following drug administration (data not thermore, there is the possibility of slight inaccuracies in the shown). The variable and transient changes seen were glucuronide determinations in urine owing to the indirect believed to be associated with frequent blood collections for analytical methodology employed and the low glucuronide pharmacokinetic studies during the first 24 h following drug concentrations relative to those of FTC and FTU. administration. All animals, including the control, showed Concentrations of FTC and the metabolite FTU in CSF slight, transient increases in creatine phosphokinase, serum after i.v. and p.o. administrations of the parent nucleoside glutamic oxalacetic transaminase, serum glutamic pyruvic are illustrated in Fig. 1 and 2 , respectively. The ratios of transaminase,'and lactate dehydrogenase during the first 24 h nucleoside concentrations in CSF-serum for FTC and FTU following drug administration. Since comparable elevations (2, 15, 19, 23) . Thus, the rhesus monkey appears to be an excellent animal model for examining the pharmacokinetics of nucleoside analogs. FTC is a novel cytidine derivative with potent and selective anti-HIV and anti-HBV activity in vitro (10, 11, 13, 24) . However, the deaminated form of FTC, FTU, is inactive in human peripheral blood mononuclear cells infected with HIV-1 or liver cells (2.2.15 cells) transfected with HBV (10, 13) . Tissues and blood of rhesus monkeys have a very high level of deaminase activity, whereas in humans this activity is found primarily in the liver (3) . This raises the possibility that FTC could be converted to FTU in monkeys and possibly in humans. We had previously demonstrated that cytosine-containing antiviral nucleosides, such as 3'-azido-2',3'-dideoxy-5-methylcytidine, are deaminated in monkeys but not in rats (25) . This is expected, since rats have no measurable deaminase activity (3). Thus, it was important to determine the precinical pharmacokinetics of FTC by using the rhesus monkey as an animal model that is closer to humans.
FTC is structurally similar to the anti-HIV agent DDC.
The structural differences between FTC and DDC are (i) the presence of a sulfur atom instead of a methylene group at the 3' position of the furanose ring normally found in natural nucleosides and (ii) a fluorine atom instead of a hydrogen atom at the 5 position of the nucleoside base. FTC consists of two compounds that are mirror images of each other (enantiomers) in equal proportions, known as the (+)-and (-)-enantiomers. Another, similar nucleoside analog with anti-HIV activity is 2',3'-dideoxy-3'-thiacytidine (BCH-189) (1, 6, 26, 32) ; however, the pharmacokinetics of this compound in a mammal have not been reported. The (-)-enantiomers of FTC and BCH-189 (also known as 3TC) were more potent against HIV-1 than was the (+)-compound in acutely infected primary lymphocytes (24) .
FTC was eliminated at a moderate to high rate with CLr values that approached hepatic blood flow and renal serum flow rates (12) . The nucleoside appeared to be distributed intracellularly and to accumulate in at least some tissues in the body, since its steady-state volume of distribution (2.23 liters/kg) was three-to fourfold greater than that of the total body water of the monkey (12) . FTC was absorbed rapidly after p.o. administration, with a t1/ for absorption of approximately 0.5 h. The extent of absorption was incomplete, yet substantial, with an oral F of 73%.
The CLr of FTC (1.49 liters/h/kg) in monkeys was approximately twofold greater than that of DDC (0.65 liters/h/kg) in rhesus monkeys (15 Fig. 1 and 2 (30) . A critical facet of anti-HIV drug therapy is the ability of the agent to inhibit viral replication within the central nervous system (14, 18 drug administration probably underestimates the equilibrium ratio. The metabolite FTU was also detected in the CSF, with a drug concentration ratio for CSF-serum of 0.038 1 h after FTC administration. The CSF-serum DDC concentration ratio of 0.033 at 1 h (15) was less than that determined for FTC.
There was no evidence of clinical, hematological, or blood chemistry changes that could be attributed to FTC administration in any of the experimental animals following i.v. or p.o. administration of the drug at 33.3 mg/kg. However, it should be noted that this was a short-term follow-up after a one-time drug administration, and this should not be considered as evidence for lack of toxicity that might be associated with chronic administration of FTC.
In summary, the pharmacokinetics of FTC in rhesus monkeys were, in general, similar to those of other anti-HIV-1 nucleosides (2, 15, 19, 23, 25 (11, 24, 27) . The finding that the L-(-)-form of FTC is a more potent and less toxic enantiomer against HIV and HBV in cell culture and is also more resistant to deamination suggests that this compound should be further evaluated instead of racemic FTC or (+)-FTC. Initial studies with radiolabeled (-)-FTC indicate that this compound is not deaminated or racemized in rhesus monkeys. In addition, three previously unrecognized minor metabolites, 5-fluorocytosine and the two sulfoxides of FTC, were detected and characterized (28) . The extent to which (-)-FTC is a viable alternative to currently available anti-HIV and anti-HBV agents remains to be determined.
